Physicians' Academy for Cardiovascular Education

A new era for CV risk & diabetes management: Treat to earlier, broader and lower targets

Slides (presentation) - Oct. 19, 2011

A new era for CV risk & diabetes management: Treat to earlier, broader and lower targets
Global Impact of CVD
Heart Protection Study: Impact of Diabetes on CV outcome
CVD Accounts for 71% of Costs of Chronic Complications of Diabetes
Framingham Heart Study Lifetime Risk
High-Normal BP and CVD Risk: Framingham Study
Lifetime Atherosclerosis Management
UKPDS: Risk Factors for MI.
Multiple Risk Factors and CVD Death in Diabetic and Non diabetic Men (MRFIT)
Age and CV Risk in Diabetes
Benefit of Smoking Cessation
13 year old boy weighing 11.2kg more than normal runs 33% increased probability of a cardiovascular event before the age of 60
TROPHY Study: ARB in ‘Prehypertension’
Drug Treatment in CV Disease
RAS and CV Risk
Cardiovascular Continuum
RAS Blockade, Adipocytes and Diabetes
Antioxidant Action of Candesartan
CHARM-Overall: New diagnosis of Diabetes
RAS Inhibition and New DM
Disease modifying treatments
Investing in your Arteries! (Big and Little!)
BP Treatment in Type 2 DM

Share this page with your colleagues and friends: